Download PDF - Retrovirology - BioMed Central

2 downloads 0 Views 132KB Size Report
Mar 28, 2007 - The Scripps Research Institute, 10550 North Torrey Pines Rd. La Jolla, CA 92037, USA, 3National Institute for Communicable Diseases,.
Retrovirology

BioMed Central

Open Access

Correction

Correction: Inhibition of HIV Env binding to cellular receptors by monoclonal antibody 2G12 as probed by Fc-tagged gp120 James M Binley1, Stacie Ngo-Abdalla2, Penny Moore3, Michael Bobardt4, Udayan Chatterji4, Philippe Gallay4, Dennis R Burton5, Ian A Wilson6, John H Elder2 and Aymeric de Parseval*2 Address: 1Torrey Pines Institute for Molecular Studies, 3550 General Atomics Court, San Diego CA 92121, USA, 2Department of Molecular Biology, The Scripps Research Institute, 10550 North Torrey Pines Rd. La Jolla, CA 92037, USA, 3National Institute for Communicable Diseases, Sandringham, Johannesburg 2131, South Africa, 4Department of Immunology, The Scripps Research Institute, 10666 North Torrey Pines Rd. La Jolla, CA 92037, USA, 5Department of Immunology and Molecular Biology, The Scripps Research Institute, 10666 North Torrey Pines Rd. La Jolla, CA 92037, USA and 6Department of Molecular Biology and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10666 North Torrey Pines Rd. La Jolla, CA 92037, USA Email: James M Binley - [email protected]; Stacie Ngo-Abdalla - [email protected]; Penny Moore - [email protected]; Michael Bobardt - [email protected]; Udayan Chatterji - [email protected]; Philippe Gallay - [email protected]; Dennis R Burton - [email protected]; Ian A Wilson - [email protected]; John H Elder - [email protected]; Aymeric de Parseval* - [email protected] * Corresponding author

Published: 28 March 2007 Retrovirology 2007, 4:23

doi:10.1186/1742-4690-4-23

Received: 26 March 2007 Accepted: 28 March 2007

This article is available from: http://www.retrovirology.com/content/4/1/23 © 2007 Binley et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

After publication of our work [1], we noted that panel C from figure 4 (see Figure 1) was missing. We have now added the corrected figure.

Page 1 of 3 (page number not for citation purposes)

Retrovirology 2007, 4:23

% residual infection

A)

http://www.retrovirology.com/content/4/1/23

b12 (CD4bs)

120 100

standard post-CD4

80 60 40 20 0 0.001

0.01

0.1

1

10

mAb concentration (µg/ml)

% residual infection

B)

X5 (CD4i)

120 100 80 60

standard post-CD4

40 20 0 0.001

0.01

0.1

1

10

mAb concentration (µg/ml)

% residual infection

C)

120

2G12 (high mannose)

100 standard post-CD4

80 60 40 20 0 0.001

0.01

0.1

1

10

mAb concentration (µg/ml) formats Figure CD4 b12, (closed Figure B) assay 4.X5, circles) 12G12 format. andneutralizes and C) The 2G12 post-CD4 neutralization was HIV-1 assessed (open JR-CSF circles) activity ineffectively theneutralization standard of mAbs in aA) postFigure 4. 2G12 neutralizes HIV-1 JR-CSF effectively in a postCD4 assay format. The neutralization activity of mAbs A) b12, B) X5, and C) 2G12 was assessed in the standard (closed circles) and post-CD4 (open circles) neutralization formats. Results are expressed as % of residual infection, with 100% representing infection in the absence of mAb. Results are representative of two experiments.

Page 2 of 3 (page number not for citation purposes)

Retrovirology 2007, 4:23

http://www.retrovirology.com/content/4/1/23

References 1.

Binley JM, Ngo-Abdalla S, Moore P, Bobardt M, Chatterji U, Gallay P, Burton DR, Wilson IA, Elder JH, de Parseval A: Inhibition of HIV Env binding to cellular receptors by monoclonal antibody 2G12 as probed by Fc-tagged gp120. Retrovirology 2006, 3:39.

Publish with Bio Med Central and every scientist can read your work free of charge "BioMed Central will be the most significant development for disseminating the results of biomedical researc h in our lifetime." Sir Paul Nurse, Cancer Research UK

Your research papers will be: available free of charge to the entire biomedical community peer reviewed and published immediately upon acceptance cited in PubMed and archived on PubMed Central yours — you keep the copyright

BioMedcentral

Submit your manuscript here: http://www.biomedcentral.com/info/publishing_adv.asp

Page 3 of 3 (page number not for citation purposes)